The diagnosis and management of iron deficiency anaemia (IDA) remains a challenge. It is an important public health problem in Australia, with the World Health Organization (WHO) estimating that 8% of preschool children, 12% of pregnant women and 15% of non-pregnant women of reproductive age in Australia have anaemia, with IDA a major cause.

Iron metabolism: a brief overview
Most body iron (ie, 2.6g of 3–4g) circulates as haemoglobin (Hb), which is recycled when red cells senesce. One gram is stored in the liver, and 0.4g in myoglobin and cytochromes. Small amounts (3mg) circulate bound to plasma transferrin. Men and non-menstruating women lose about 1mg of body iron per day; menstruating women may lose an additional 1mg daily on average. Full-term babies are born with 180mg iron, but must double their red cell mass within 12 months (low birth weight infants need to more than double their red cell mass). Requirements escalate rapidly during adolescence with increasing blood volume and lean body mass, compounded in females by the onset of menstruation, and in pregnancy by increases in maternal red cell mass and fetal erythropoiesis.

Dietary iron comprises haem (animal sources) and non-haem iron (cereal and vegetable sources). Haem iron (bound to Hb and myoglobin) is better absorbed than non-haem iron. Non-haem iron is absorbed by intestinal luminal cells through a specific transporter (divalent metal transporter, located on the apical membrane of intestinal enterocytes), and released into the circulation where it binds to transferrin. Transferrin receptors on erythroid blasts accept iron-transferrin complexes; these undergo endocytosis and the iron is incorporated into Hb. Although the specific mechanism of haem-iron absorption remains unclear, putative transporters have been identified.1

Iron absorption is upregulated by iron deficiency and increased erythropoiesis, and downregulated in inflammation and iron repletion, mediated by the recently described regulator of iron homeostasis, hepcidin, which blocks iron release from enterocytes and macrophages.3 Body iron stores are regulated through iron absorption. Non-haem iron is best absorbed in the ferrous form (Fe2+). Reduction of ferric iron (Fe3+) by stomach acid, dietary ascorbic acid and luminal reductases optimises absorption. Non-haem iron absorption is inhibited by simultaneous consumption of phytates (in cereals and legumes), tannins (in tea) and calcium. Simultaneous consumption of haem-iron sources and ascorbic acid enhances absorption. Less than 20% of available iron is absorbed in a typical Western diet, lower still from a vegetarian diet. Recommended daily intakes of iron at different stages of life are listed in Box 1.

Causes and implications of iron deficiency
Iron deficiency results when iron losses or requirements exceed absorption, and is often multifactorial. It is common in children

ABSTRACT
• Iron deficiency anaemia (IDA) remains prevalent in Australia and worldwide, especially among high-risk groups.
• IDA may be effectively diagnosed in most cases by full blood examination and serum ferritin level. Serum iron levels should not be used to diagnose iron deficiency.
• Although iron deficiency may be due to physiological demands in growing children, adolescents and pregnant women, the underlying cause(s) should be sought.
• Patients without a clear physiological explanation for iron deficiency (especially men and postmenopausal women) should be evaluated by gastroscopy/colonoscopy to exclude a source of gastrointestinal bleeding, particularly a malignant lesion.
• Patients with IDA should be assessed for coeliac disease.
• Oral iron therapy, in appropriate doses and for a sufficient duration, is an effective first-line strategy for most patients.
• In selected patients for whom intravenous (IV) iron therapy is indicated, current formulations can be safely administered in outpatient treatment centres and are relatively inexpensive.
• Red cell transfusion is inappropriate therapy for IDA unless an immediate increase in oxygen delivery is required, such as when the patient is experiencing end-organ compromise (eg, angina pectoris or cardiac failure), or IDA is complicated by serious, acute ongoing bleeding.
• Consensus methods for administration of available IV iron products are needed to improve the utilisation of these formulations in Australia and reduce inappropriate transfusion.
• New-generation IV products, supported by high-quality evidence of safety and efficacy, may facilitate rapid administration of higher doses of iron, and may make it easier to integrate IV iron replacement into routine care.

*The authors are members of the Australian Iron Deficiency Expert Group, comprising health professionals from diverse backgrounds with a shared interest in alleviating the burden and optimising management of iron deficiency anaemia (IDA) in Australia. Formation of the expert group was an initiative of the Australian and New Zealand Society of Blood Transfusion, supported by the Australian Red Cross Blood Service, New South Wales Clinical Excellence Commission (Blood Watch program), Victorian Department of Health (Blood Matters program) and South Australian Department of Health (BloodSafe program). During a meeting in May 2009, the expert group conducted a barrier analysis around improving the diagnosis and management of IDA in Australia. Many common clinical misconceptions were identified and thus developing a national education strategy was given high priority. A writing group was formed to provide a clinical update specific for the Australian setting.
during rapid growth and erythroid expansion, especially in premature or low birth weight babies, in toddlers and preschool children, and during adolescence. Pregnancy results in an overall additional iron requirement of about 1000 mg.\(^3\) Breastfeeding removes 1 mg of iron per day, but losses are mitigated by lactation-induced amenorrhea if present. Blood loss is the most important cause of iron deficiency in adults. Each millilitre of blood loss (if Hb is 150 g/L) results in loss of around 0.5 mg of iron. Gastrointestinal (GI) blood loss is the most important cause in postmenopausal women and men. While menstrual blood loss commonly causes IDA in premenopausal women, coexistent GI lesions have often been identified. Malabsorption of iron may be caused by intestinal mucosal disorders (most frequently, coeliac disease), impaired gastric acid secretion (including use of proton pump inhibitors), and gastric/intestinal bypass procedures. Helicobacter pylori colonisation is also associated with IDA and may impair iron uptake and increase iron loss.\(^4\) Anaemia in endurance athletes (“sports anaemia”) has been associated with iron deficiency (due to reduced iron intake, impaired absorption caused by elevated hepcidin, GI bleeding and sweat losses), as well as mechanical haemolysis and haemodilution.\(^5\)

IDA is associated with impaired cognitive development in preschool-aged children and diminished work productivity and cognitive and behavioural problems in adults.\(^6,7\)

Among pregnant women, IDA has been associated with increased risks of low birth weight, prematurity and maternal morbidity.\(^8\) Non-anaemic tissue iron deficiency may cause impairment in both adults\(^9\) and children.\(^10\) In a recent randomised trial, patients with chronic heart failure and iron deficiency (both with and without anaemia) treated with intravenous (IV) iron carboxymaltose experienced improvements in symptoms, functional capacity and quality of life, independent of Hb concentrations.\(^10\)

**Epidemiology of IDA**

Few studies have reported the prevalence of iron deficiency or anaemia in the Australian population. Among toddlers, studies in Sydney and Adelaide suggest IDA prevalence ranges from 1%–6%, and up to 14% in Asian groups.\(^11-13\) Other studies show the prevalence of anaemia (all causes) among non-pregnant young women to be 10%,\(^14\) and 11% in pregnant women not taking iron supplements.\(^15\) Anaemia is highly prevalent in Indigenous communities; a study in an Aboriginal community of Western Australia identified anaemia among 55% of women and 18% of men.\(^16\) United States data show that 11% of men and 10% of women older than 65 years have anaemia, with iron deficiency accounting for 20%.\(^17\) Other high-risk groups include blood donors, where the prevalence of iron deficiency among females exceeds 20%.\(^18\)

![Recommended daily dietary iron intakes for Australians*](image)

**Diagnosis and evaluation of IDA**

Anaemia is defined as a Hb concentration below the reference range (specific for age, sex and gestation) for the laboratory performing the test. The WHO defines anaemia as a Hb level below 130 g/L in men, 120 g/L in women, and 110 g/L in pregnant women and preschool children.\(^19\)

Iron deficiency should be distinguished from other causes of anaemia because of its associations with underlying conditions that mandate specific investigation, and because treatment is simple, safe and effective. Anaemia with low mean corpuscular volume (MCV) or mean corpuscular haemoglobin (MCH) is likely to be due to iron deficiency; the important differential diagnoses are thalassaemic conditions, which should be excluded as clinically appropriate. A strategy for assessment and management of IDA is outlined in Box 2.

Patients with suspected iron deficiency should have iron studies performed and the results correlated with red cell indices. Box 3 provides guidance for interpretation of results of laboratory tests of iron status. The serum ferritin level is the most readily available and useful index of iron deficiency.\(^22\) In an anaemic adult, a ferritin level below 15 g/L is diagnostic of iron deficiency, and levels between 15 and 30 g/L are highly suggestive. Lower thresholds (from 10 to 12 g/L) have been used for children.\(^19,20\) However, ferritin is also an acute-phase protein and is elevated in inflammation, infection, liver disease and malignancy. This can result in misleadingly elevated ferritin levels in iron-deficient patients with coexisting systemic illness. In the elderly or among patients with inflammation, iron deficiency may still be present with ferritin values up to 60–100 g/L.\(^23,24\) Markers such as C-reactive protein may help identify coexisting inflammation. Serum iron levels have significant diurnal variation, are low in both iron deficiency and inflammation, and should not be used to diagnose iron deficiency.

Functional iron deficiency (FID) exists when, despite adequate stores, iron cannot be mobilised for erythropoiesis, mediated by elevated hepcidin. It is commonly seen in patients with end-stage kidney disease, whose response to erythropoietin-stimulating agents may be optimised when ferritin levels exceed 200 g/mL.\(^25\) FID may also contribute to anaemia in patients with inflammatory diseases such as rheumatoid arthritis. Percentage hypochromic red cells and reticulocyte haemoglobin content (available on some automated haematology analysers) have been used to assess iron status in patients receiving erythropoietin-stimulating agents and may be a useful indicator of FID.\(^26,27\)

An additional iron index is the soluble transferrin receptor (sTIR) concentration, which is elevated in tissue iron deficiency and not sensitive to inflammation; the sTIR/log ferritin ratio is highly correlated with body iron stores.\(^28\) However, sTIR estimation is limited by variability in interassay cut-offs, availability and slow turnaround in some laboratories. Bone marrow examination remains the gold-standard investigation of IDA in complex cases.
2 Iron deficiency anaemia (IDA): assessment and management*

<table>
<thead>
<tr>
<th>Anaemia*</th>
<th>Hb below laboratory reference range for age, sex, gestation (full history and physical examination is essential in all cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum ferritin &lt; 15–30 μg/L in adults† Serum ferritin &lt; 10–12 μg/L in children (see Box 3): Confirmed IDA‡</td>
<td>MCV may be normal in early IDA or with coexisting vitamin B₁₂ or folate deficiency</td>
</tr>
<tr>
<td>Serum ferritin &gt; 15–30 μg/L but &lt; 100 μg/L (see Box 3): Possible IDA‡</td>
<td>Iron deficiency is not excluded in the presence of inflammation, chronic disease or high CRP</td>
</tr>
<tr>
<td>Serum ferritin &gt; 100 μg/L: IDA unlikely</td>
<td>• Identify alternative cause(s) of anaemia</td>
</tr>
<tr>
<td>† The underlying cause of all cases of IDA should be determined, regardless of the severity.</td>
<td></td>
</tr>
<tr>
<td>‡ The underlying cause of all cases of IDA should be determined, regardless of the severity.</td>
<td></td>
</tr>
<tr>
<td>§ The underlying cause of all cases of IDA should be determined, regardless of the severity.</td>
<td></td>
</tr>
</tbody>
</table>

** Algorithm is a guide only — each case should be evaluated based on particular clinical history, examination and results of investigations. 

ACD = anaemia of chronic disease. CKD = chronic kidney disease. CRP = C-reactive protein. ESAs = erythropoietin-stimulating agents. FID = functional iron deficiency. GI = gastrointestinal. Hb = haemoglobin. IV = intravenous. MCV = mean cell volume. sTfR = soluble transferrin receptor. Tfsat = transferrin saturation %.

Consistent with IDA
Review clinical findings for possible underlying pathology and sources of overt and occult blood loss (eg, GI, genitourinary, nose, mouth, blood donation)*

Preschool children‡
Consider:
• Inadequate dietary iron
• Inadequate complementary foods (eg, excess milk ingestion)
• Cow’s milk allergy
• Rapid/rebound growth, former low birth weight
• Coeliac disease
• Parasitic infection
• GI blood loss

Older children
Consider:
• Inadequate dietary iron (especially if vegetarian)
• Rapid/rebound growth
• Coeliac disease
• Parasitic infection
• GI blood loss

Adolescent and premenopausal women‡
Consider:
• Inadequate iron intake
• Blood loss (eg, menorrhagia, GI, haemostatic defect)
• Coeliac disease
• Parasitic infection

Risk factors for GI pathology:
• GI symptoms
• Family history of colorectal cancer
• Age > 50 years
• Refractory, recurrent or unexplained IDA

Adult men and postmenopausal women
Exclude:
• GI blood loss (eg, neoplasm)
• Coeliac disease

Investigations:
• Gastroscopy/colonoscopy
• Coeliac screening
• Others as directed by clinical findings and context

Treatment (Box 4):
• Oral iron (usually 100–200 mg elemental iron per day**) for at least 3 months after normalisation of Hb
• IV iron for selected patients (see Box 6)
• Optimise dietary iron (secondary prevention) and address underlying cause

Treatment (see Box 4):
• Oral iron liquid (3–6 mg/kg elemental iron per day)
• Optimise dietary iron content

Although it can usually be avoided. Hepcidin may emerge as a useful aid for assessment of iron status. Where the diagnosis is unclear, clinicians should seek guidance from their pathologist or another relevant expert.

Management of IDA
A recommended approach to assessment and management of IDA is outlined in Box 2. The underlying cause must be established in all patients. Importantly, in men and postmenopausal women with IDA, and also in some premenopausal women, evaluation for benign or malignant GI lesions, inflammatory conditions (such as inflammatory bowel disease) and peptic ulceration is indicated. Screening for coeliac disease should be performed.⁴,²⁹

Dietary therapy
Increasing dietary iron intake alone is inadequate to treat frank IDA and higher supplemental doses of iron are required (Box 4). However, increasing iron consumption and optimising absorption by minimising inhibitors and maximising enhancers may be valuable for secondary prevention of iron deficiency. Recommended daily dietary intake of iron at different ages is presented in Box 1.
**Oral therapies**

Although more than 100 preparations containing iron are available over the counter in Australia, few contain sufficient elemental iron to treat IDA effectively. The usual recommended dose of oral iron for the treatment of IDA in adults is 100–200 mg of elemental iron daily or in 2 to 3 divided doses;30 recommended doses for children are 3–6 mg/kg/day of elemental iron.20,31 Appropriate formulations are presented in Box 4. Multivitamin-mineral supplements should not be used to treat IDA as iron content is low and absorption may be reduced.

Studies in women and children have shown lower doses of oral iron may be effective and associated with fewer GI side effects.32 In adults, lower doses can be administered through either intermediate-dose tablets (containing around 30–60 mg of elemental iron) or intermittent dosing (eg, second daily to weekly); the latter approach has been recommended by the WHO for some developing countries. Either approach may be useful in patients with mild IDA who experience GI upset with standard doses of iron, but rapid Hb rise is not essential; however, appropriate intermediate-dose iron tablets are not available in Australia. GI upset may also be reduced by taking the dose with food or at night.

When given at equivalent elemental iron doses, different oral iron salts have similar efficacy and tolerability. Based on limited available data, controlled-release iron formulations appear to have fewer GI side effects, but similar discontinuation rates and comparable efficacy,33 release of iron distal to the site of maximal intestinal absorption may theoretically limit response in some patients.

After therapeutic doses of oral iron, reticulocytosis should occur within 72 hours, and Hb levels should rise by about 20 g/L every 3 weeks. It is reasonable to replenish iron stores by continuing treatment for 3–6 months (2–3 months in children30) beyond normalisation of Hb. Causes of failure to respond to oral iron are listed in Box 5. If IDA recurs following repletion of iron stores, a bleeding source must be vigorously sought.

**Parenteral iron therapy**

**Intramuscular (IM) iron therapy**

Although IM injection of iron is effective, it is painful, associated with permanent skin staining and no safer than IV infusion. Its use is therefore discouraged34 unless other approaches cannot be practically delivered (eg, when parenteral iron is indicated in remote settings).

**Intravenous (IV) iron therapy**

While oral iron remains the cornerstone of IDA therapy, some patients require IV iron therapy (Box 6). Underuse of IV iron may have stemmed in part from concerns about the risk of serious allergic reactions — for example, 0.6% of patients treated with high molecular weight iron dextran (no longer available in Australia) had life-threatening allergic reactions.35 Iron polymaltose (Ferrum H [Aspen Pharmacare], Ferrosig [Sigma Pharmaceuticals]) and iron sucrose (Venofer [Aspen Pharmacare]) are the parenteral iron formulations currently available in Australia. A “total-dose” infusion (where iron stores can be repleted in a single treatment episode) can be administered only with iron polymaltose.

**Iron polymaltose**

Although iron polymaltose (iron dextrin) has been widely used in Australia since the 1960s, there is limited literature concerning its safety, particularly outside the nephrology setting. An Australian audit of the inhospital safety and tolerability of iron polymaltose identified no cases of anaphylaxis or other cardiorespiratory
4 Commercially available forms of iron therapy in Australia suitable for the treatment of iron deficiency anaemia (IDA)*

Dosing is based on elemental iron content.

To avoid confusion, clinicians should write the name of the oral preparation(s) recommended for the patient to take to the pharmacist. Ingestion of even a small amount of iron can be fatal in infants and young children; patients should be advised to keep iron supplements out of reach of children and never give their child an adult dose.

### Oral formulations for adults

<table>
<thead>
<tr>
<th>Name of preparation (company)</th>
<th>Formulation</th>
<th>Elemental iron content</th>
<th>Other active ingredients</th>
<th>Relative cost$</th>
</tr>
</thead>
<tbody>
<tr>
<td>FERRO-GRADUMET (Abbott Australasia)</td>
<td>Ferrous sulfate 325 mg Controlled-release tablets</td>
<td>105 mg</td>
<td>Nil</td>
<td>MIMS: $6.56 per 30 tablets; 22 cents per tablet</td>
</tr>
<tr>
<td>FERROGRAD C (Abbott Australasia)</td>
<td>Ferrous sulfate 325 mg Controlled-release tablets</td>
<td>105 mg</td>
<td>Vitamin C 500 mg</td>
<td>MIMS: $8.16 per 30 tablets; 27 cents per tablet</td>
</tr>
<tr>
<td>FGF (Abbott Australasia)</td>
<td>Ferrous sulfate 250 mg Controlled-release tablets</td>
<td>80 mg</td>
<td>Folic acid 300 μg</td>
<td>MIMS: $3.92 per 30 tablets; 13 cents per tablet</td>
</tr>
<tr>
<td>FEFOL iron and folate supplement (Pharmacare Laboratories)</td>
<td>Ferrous sulfate 270 mg Controlled-release capsules</td>
<td>87 mg</td>
<td>Folic acid 300 μg</td>
<td>MIMS: $9.95 per 30 tablets; 33 cents per tablet</td>
</tr>
<tr>
<td>FERRO-F-TAB (AFT Pharmaceuticals)</td>
<td>Ferrous fumarate 310 mg Non-controlled-release tablets</td>
<td>100 mg</td>
<td>Folic acid 350 μg</td>
<td>PBS: $12.79 per 60 tablets; 21 cents per tablet</td>
</tr>
</tbody>
</table>

### Oral formulation for children or adults requiring a liquid

<table>
<thead>
<tr>
<th>Name of preparation (company)</th>
<th>Formulation</th>
<th>Elemental iron content</th>
<th>Other active ingredients</th>
<th>Relative cost$</th>
</tr>
</thead>
<tbody>
<tr>
<td>FERRO-LIQUID (AFT Pharmaceuticals)</td>
<td>Ferrous sulphate Oral liquid 150mg/5mL</td>
<td>30 mg/5mL</td>
<td>Nil</td>
<td>PBS: $19.35 per 250mL bottle</td>
</tr>
</tbody>
</table>

### Intravenous formulations

<table>
<thead>
<tr>
<th>Name of preparation (company)</th>
<th>Formulation</th>
<th>Elemental iron content</th>
<th>Other active ingredients</th>
<th>Relative cost$</th>
</tr>
</thead>
<tbody>
<tr>
<td>FERRUM H (Aspen Pharmacare)</td>
<td>Iron polymaltose</td>
<td>100 mg ampoules</td>
<td>Nil</td>
<td>PBS: $50.36 per 5 ampoules</td>
</tr>
<tr>
<td>FERROSIG (Sigma Pharmaceuticals)</td>
<td>Iron polymaltose</td>
<td>100 mg ampoules</td>
<td>Nil</td>
<td>PBS: $50.36 per 5 ampoules</td>
</tr>
<tr>
<td>VENOFER‡‡ (Aspen Pharmacare)</td>
<td>Iron sucrose</td>
<td>100 mg ampoules</td>
<td>Nil</td>
<td>PBS: $139.48 per 5 ampoules</td>
</tr>
</tbody>
</table>

PBS = Pharmaceutical Benefits Scheme.

* Multivitamin-mineral supplements should not be used to treat IDA (iron content is low and absorption may be reduced).
† Amounts indicate relative cost (not price to consumer) based on 2010 MIMS price guide (MIMS Online, CMPMedica Australia, Oct 2010) and PBS schedule (dispensed price for maximum quantity).
‡ Usual adult dosing: 100–200 mg of elemental iron per day (1–2 tablets), taken 1 hour before or 2 hours after meals in divided doses. Gastrointestinal upset may be reduced by taking the dose with food or at night and increasing the number of tablets gradually. Lower daily doses or intermittent dosing (2–3 times per week) may be better tolerated when a rapid increase in Hb is not required.
§ Paediatric dosing: 3–6 mg/kg of elemental iron per day (3 mg/kg per day is 5 mL of Ferro-liquid in a 10 kg child) taken in divided doses.
¶ Calculation of total iron deficit is based on Hb and weight: iron deficit (mg) = lean body weight (kg) x 0.24 x [target Hb – actual Hb (g/L)] + iron depot. Iron depot (store) is around 500 mg in adults.
** Intravenous formulations are contraindicated in the first trimester of pregnancy.
†† Intravenous iron preparations are iron–carbohydrate complexes. The maximum dosage and infusion rates are NOT interchangeable.
‡‡ Use intermittent small doses (NOT suitable for a total-dose infusion in one treatment); currently only funded by PBS for specific indications in chronic kidney disease.

compromise in 401 infusions, and noted infrequent minor side effects during infusion. This concurs with the clinical experience of several members of our group. Self-limited side effects that occur up to 2 days after infusion, including headache, fever and arthralgias, are common, affecting 26% of patients in a recent study. An average total-dose infusion of iron polymaltose (sufficient to replenish iron stores, commonly 1000 mg–2500 mg for adults), given at the rates recommended in Australian approved product information, takes around 5 hours. A recent survey of policies at different New South Wales health services found a broad range of infusion and premedication practices. Few published data indicate the fastest safe rate for either total-dose infusions or smaller dose infusions given in the renal setting (500–1000 mg or less). Several Australian nephrology units have developed protocols and used accelerated infusion rates (Rowan Walker, Deputy Director of Nephrology, Royal Melbourne Hospital, Victoria, and Ashley Irish, Senior Staff Nephrologist, Royal Perth Hospital, Western Australia, personal communications). Delivery of total-dose iron polymaltose infusions at accelerated rates have been safely administered by some of the authors (S C F-B, RT, P R G) in specialist outpatient treatment centres, with and without routine premedication. Accounts of this experience should be published through prospective clinical studies in Australia and New Zealand because use of iron polymaltose outside these countries is limited. We are not aware of accelerated administration of iron polymaltose in children.
5 Major reasons for inadequate response to oral iron therapy*

- Inadequate iron intake:
  - Patient not taking oral iron therapy
  - Patient taking an iron supplement or multivitamin tablet with insufficient iron content

- Inadequate iron absorption:
  - Concomitant consumption of inhibitors of iron absorption (eg, tea, calcium, antacids, tetracycline, within 2 hours of iron ingestion)
  - Coexisting inflammation with functional iron deficiency
  - Intestinal mucosal disorders (eg, coeliac disease, inflammatory bowel disease)
  - Impaired gastric acid secretion (including use of proton pump inhibitors)

- Coexisting condition interfering with bone marrow response:
  - Ongoing primary bone marrow disease or suppression

- Incorrect diagnosis or more than one cause of anaemia:
  - Anaemia of chronic disease or renal failure
  - Haemoglobinopathy
  - Other causes of anaemia (eg, haemolysis, myelodysplastic syndromes, congenital anaemia, endocrine disorders)

*More than one factor is often present. †Role is unclear (limited available data show efficacy comparable to that of non-controlled-release formulations).  

Iron sucrose

Iron sucrose is funded by the Pharmaceutical Benefits Scheme for iron deficiency only in patients with chronic kidney disease who are having an erythropoietin-stimulating agent and react systemically to iron polymaltose. However, it has been licensed for treatment of IDA in Europe for decades and has a well-documented safety profile. It cannot be given as a single total-dose infusion (due to IDA in Europe for decades and has a well-documented safety to iron polymaltose. However, it has been licensed for treatment of having an erythropoietin-stimulating agent and react systemically iron deficiency only in patients with chronic kidney disease who are

There are a number of new IV iron preparations. Iron carboxymaltose, which is available in Europe but has not yet been granted marketing approval in Australia, appears to have a low risk of serious adverse effects, and infusions of 1000 mg can be given over 15 minutes. Other preparations available internationally include low molecular weight iron dextran, iron gluconate and ferumoxytol.

Red cell transfusion

Transfusion of red cells remains an overused treatment for IDA. It is also expensive and potentially hazardous. In physiologically compensated patients, transfusion carries unnecessary risks and fails to replenish deficient iron stores. Adequate doses of oral iron can improve Hb concentrations within a few weeks, and IV iron can provide more rapid and predictable increases when clinically important. Transfusion is associated with adverse outcomes, including fluid overload (around 1% of patients), and a range of immunological and infectious hazards. Hence, it should be
reserved for immediate, targeted management in patients with severe anaemia compromising end-organ function (eg, angina pectoris or cardiac failure) or where IDA is complicated by serious, acute ongoing bleeding. Iron therapy should always follow transfusion to replenish iron stores.

Conclusion
IDA remains a common and important disorder. Measures to alleviate the burden of IDA in Australia should include strategies to increase awareness of the problem among clinicians and the general public, improved availability of suitable oral formulations, enhanced access to modern IV iron therapies, and prospective studies of the epidemiology, investigation and treatment of IDA, which would inform the development of best practice guidelines.

Competing interests
Katrina Allen gave a presentation at an educational forum on iron therapy organised by Aspen Pharmacare in February 2008 and received an honorarium for her time. She received reimbursement for local travel expenses. (Aspen are the Australian sponsors for iron sucrose and iron polymaltose on behalf of Vifor International.) Peter Gibson has received honoraria from Aspen Pharmacare for contributing to educational meetings. His institution has received a grant from Vifor International for an investigator-initiated study. Simon Roger has received money for board membership of, and consultancy for, Amgen, Roche, Vifor, Janssen-Cilag and Sandoz. He has also received honoraria, payment for educational presentations and reimbursement for travel expenses from these companies. Kathryn Robinson had an interstate airfare and accommodation for one night paid directly by Aspen Pharmacare for presenting at an educational forum organised by Aspen in February 2008, information from her presentation was used for an Aspen educational newsletter but no payment was received.

The Australian Iron Deficiency Expert group received funding for a meeting in May 2009 from the Australian and New Zealand Society of Blood Transfusion, the Australian Red Cross Blood Service, the South Australian Department of Health, the Victorian Department of Health and the NSW Clinical Excellence Commission. The funding was used to pay for the venue and for travel and accommodation of those participants not funded by the institutions they worked for. The participants included clinicians from public hospitals and private practice, and representatives from the Australian Red Cross Blood Service, National Institute of Clinical Studies, National Prescribing Service, National Blood Authority, Therapeutic Goods Authority, and Australian Safety and Quality Commission. No funding from industry was received by the Expert group and no industry representatives were present at the meeting. Three international clinicians attending the Expert meeting were in Australia (funded by Vifor International) for a meeting organised by the WA Department of Health Blood Management Program — the Expert group meeting was organised back-to-back with this meeting to take advantage of their visit.

Author details
Sant-Rayn S Pasricha, MB BS, MPH, Haematology and Transfusion Medicine Registrar1,2
Stephen C Flecknoe-Brown, MB BS, FRACP, FRCPath, Physician,3 and Senior Lecturer4
Katrina J Allen, MB BS, FRACP, PhD, Paediatric Gastroenterologist and Allergist,5 and Group Leader6
Peter R Gibson, MD, FRACP, Professor of Medicine,7 and Director of Gastroenterology and Hepatology8
Lawrence P McMahon, MD, BS, FRACP, Professor of Nephrology,7 and Director of Renal Medicine9
John K Olynyk, MB BS, MD, FRACP, Gastroenterologist and Hepatologist,10 and Professor, School of Medicine and Pharmacology11,12,13
Simon D Roger, MD, FRACP, Nephrologist14
Helen F Savoia, MB BS, FRCPath, Haematologist15

References

Correspondence: krobinson@arcbs.redcross.org.au


34 Solomon MW, Schumann K. Intramuscular administration of iron dextran is inappropriate for treatment of moderate pregnancy anaemia, both in intervention research on underprivileged women and in routine prenatal care provided by public health services. Am J Clin Nutr 2004; 79: 1-3.


(Received 1 Mar 2010, accepted 22 Jun 2010)